Home Newsfeeds Needham Reiterates Buy on AtriCure, Maintains $58 Price Target

Needham Reiterates Buy on AtriCure, Maintains $58 Price Target

Needham analyst Mike Matson reiterates AtriCure (NASDAQ:ATRC) with a Buy and maintains $58 price target.

byBenzinga Newsdesk

February 22, 2023

1 minute read

Needham analyst Mike Matson reiterates AtriCure (NASDAQ:ATRC) with a Buy and maintains $58 price target.

Incyte Faces Increased Competition From Emerging JAK Inhibitors, RBC Capital Lowers Price Target

By Priya Nigam

April 10, 11:25 AM

Shares of Incyte Corporation (NASDAQ: INCY) recovered last week, after having been under pressure on setbacks to its LIMBER Program.

INCY

Craig-Hallum Maintains Buy on Teradata, Raises Price Target to $48

By Benzinga Newsdesk

February 14, 10:11 AM

Craig-Hallum analyst Chad Bennett maintains Teradata (NYSE:TDC) with a Buy and raises the price target from $40 to $48.

TDC

American Equity Shareholders Gain: Analyst Explores Brookfield Reinsurance Acquisition

By Lekha Gupta

July 6, 1:57 PM

RBC Capital Markets analyst Scott Heleniak downgraded American Equity Investment Life Holding Co (NYSE: AEL) to Sector Perform from Outperform at an increased

AEL

Express Debt Overview

By Benzinga Insights

December 30, 1:08 PM

Over the past three months, shares of Express Inc. (NYSE:EXPR) fell by 17.38%. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its financials.

EXPR

Needham Reiterates Buy on AtriCure, Maintains $58 Price Target

Related Posts

Incyte Faces Increased Competition From Emerging JAK Inhibitors, RBC Capital Lowers Price Target

Craig-Hallum Maintains Buy on Teradata, Raises Price Target to $48

American Equity Shareholders Gain: Analyst Explores Brookfield Reinsurance Acquisition

Express Debt Overview